HC Wainwright Cuts Neurogene (NASDAQ:NGNE) Price Target to $65.00

Neurogene (NASDAQ:NGNE) had its target price trimmed by HC Wainwright from $70.00 to $65.00 in a report released on Wednesday morning, MarketBeat Ratings reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Neurogene’s Q3 2026 earnings at ($1.36) EPS, Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($5.44) EPS, Q1 2027 earnings at ($1.22) EPS, Q2 2027 earnings at ($1.24) EPS, Q3 2027 earnings at ($1.26) EPS, Q4 2027 earnings at ($1.27) EPS and FY2027 earnings at ($4.99) EPS.

NGNE has been the subject of several other reports. UBS Group set a $70.00 price objective on shares of Neurogene in a research note on Wednesday, June 3rd. Guggenheim assumed coverage on Neurogene in a research report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research note on Friday, July 17th. Finally, Rodman & Renshaw began coverage on Neurogene in a research report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $83.67.

Neurogene Stock Up 1.4%

NGNE stock opened at $36.14 on Wednesday. The firm has a 50 day moving average of $34.11 and a 200 day moving average of $26.90. The stock has a market capitalization of $723.16 million, a PE ratio of -7.18 and a beta of 1.70. Neurogene has a 52 week low of $15.93 and a 52 week high of $43.66.

Neurogene (NASDAQ:NGNE) last released its earnings results on Tuesday, August 11th. The company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.42) by ($0.11). On average, equities research analysts expect that Neurogene will post -5.55 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Christine Mikail Cvijic sold 4,200 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00. Following the sale, the chief financial officer directly owned 84,040 shares of the company’s stock, valued at $3,036,365.20. This trade represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 9,600 shares of company stock worth $339,932 over the last quarter. 11.68% of the stock is owned by company insiders.

Institutional Trading of Neurogene

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Neurogene in the second quarter valued at $33,274,000. Balyasny Asset Management L.P. acquired a new stake in Neurogene in the third quarter valued at approximately $12,114,000. Logos Global Management LP purchased a new stake in shares of Neurogene in the fourth quarter valued at approximately $4,017,000. Jennison Associates LLC increased its position in shares of Neurogene by 35.3% in the fourth quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after buying an additional 138,999 shares in the last quarter. Finally, Deutsche Bank AG acquired a new position in shares of Neurogene during the 2nd quarter worth approximately $3,354,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Neurogene News Roundup

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $65 price target while raising its FY2027 EPS forecast to a loss of $4.99 per share from a projected loss of $5.92. The firm also lifted its estimates for the first three quarters of 2027, indicating expectations for reduced losses over time.
• Positive Sentiment: HC Wainwright increased its Q4 2026 EPS estimate to a loss of $1.20 from $1.37 and raised its Q1–Q4 2027 estimates to losses of $1.22, $1.24, $1.26 and $1.27, respectively. These revisions suggest improving operating expectations beyond 2026.
• Positive Sentiment: Canaccord Genuity lowered its price target to $166, but the revised target remains substantially above Neurogene’s recent trading level, potentially reinforcing the stock’s significant upside narrative. Canaccord Genuity Group Lowers Neurogene Price Target
• Neutral Sentiment: HC Wainwright lowered its FY2026 EPS estimate modestly to a loss of $5.44 from $5.39 and trimmed its Q3 2026 estimate to a loss of $1.36 from $1.34. Neurogene is still expected to remain unprofitable, with consensus full-year EPS at a loss of $5.63.
• Negative Sentiment: The company’s latest quarterly results missed analyst expectations, reporting a $1.53-per-share loss versus the $1.42 consensus estimate. Continued losses and the absence of current earnings make the stock highly dependent on clinical and development progress.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.